Sesen Bio Inc.

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grant of a non-statutory stock option to one new employee in connection with the employee's commencement of employment with Sesen Bio. The addition of this new team member represents a continuation of the buildout of the Sesen Bio team in support of its transformation into a commercial-stage compa

Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

After years of brewing its medicine, Sesen is poised to gain FDA approval for Vicineum as a treatment for non-muscle-invasive bladder cancer. In the VISTA trial, Vicineum demonstrated robust efficacy which trumped all competing molecules.

Sesen Bio: Binary Event Approaching

Zomedica

Which biotech penny stocks are on your watchlist as Covid comes to an end? The post Top Biotech Penny Stocks to Buy?

Top Biotech Penny Stocks to Buy? Check These Small-Caps Out

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on Tuesday, June 1, 2021 the Company entered into a global supply agreement for Vicineum™ drug substance and drug product with the Company's partner in China, Qilu Pharmaceutical. Under the terms of the global supply agreement, Qilu Pharmaceutical will be part of the manufacturing network for gl

Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its senior leadership team with the appointment of experienced industry leaders to several key roles: Patricia Drake to Chief Commercial Officer Steve Barbera to Vice President, Market Access Julie Hoff to Vice President, Human Resources Dewey McLin to Vice President, Medical Affairs

Sesen Bio Strengthens Senior Leadership Team

The stock price of Sesen Bio Inc (NASDAQ: SESN) increased by 7.12% yesterday. This is why it happened.

SESN Stock Price: 7.12% Increase Explanation

Advaxis

T2 Biosystems

Tyme Technologies

Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Sesen Bio President and CEO Dr. Thomas Cannell will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021. Event: Jefferies Virtual Healthcare Conference Date: June 4, 2021 Time: 8:30 – 8:55 AM ET A live webcast of the Company's presentation will be access

Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference

Pieris Pharma

Protagenic Therapeutics

Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?

Best Biotech Penny Stocks in June 2021? Check These 4 Out

GT Biopharma Inc

Scopus BioPharma

These biotech penny stocks and former stocks under $5 are turning heads in the analyst community right now The post 3 Biotech Penny Stocks To Watch That Analysts Are Bullish On Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch That Analysts Are Bullish On Today

Iterum Therapeutics Plc

Marker Therapeutics Inc

Tellurian

VistaGen Therapeutics

Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now

Foresight Autonomous Hlds

IZEA

Phunware Inc

Making a penny stocks watchlist for June? Take a look at these 3 The post Top Penny Stocks to Buy Right Now?

Top Penny Stocks to Buy Right Now? 4 For Your June Watchlist

Sesen Bio, Inc. (SESN) CEO Thomas Cannell on Q1 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2021. The Company's Biologics License Application (BLA) for the Company's lead program, Vicineum, is currently under Priority Review with the Food and Drug Administration (FDA) for the treatment of BCG-unresponsive non-muscle invasive bladder can

Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™

Alfi

trivago

Hot penny stocks to watch this month. The post Penny Stocks To Watch For May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch For May 2021

Sesen Bio is seeking an accelerated approval for its NMIBC therapy, Vicineum, and the PDUFA date is coming up soon on Aug. 18.

Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its leadership team with the appointment of experienced commercial industry leader, Lisa LaMond, as Vice President, Sales and Corporate Systems. The Company also announced its engagement of leading contract sales organization (CSO), Syneos Health, for field sales support and executio

Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company's management team will host a conference call to review operating results for the first quarter ended March 31, 2021 and provide a business update. The conference call is scheduled for Monday, May 10, 2021 at 8:00 am ET. To participate in the conference call, please dial (844) 831-30

Sesen Bio to Host Conference Call to Review First Quarter 2021 Financial Results and Provide Business Update on Monday, May 10, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity “Horizons in Oncology” virtual conference on April 15, 2021. Sesen Bio will be represented by Dr. Thomas Cannell, President and CEO of Sesen Bio, who will provide a regulatory and commercial readiness update, and by Dr. Michael Jewe

Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “Horizons in Oncology” Virtual Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that leading independent proxy advisory firms Institutional Shareholder Services, Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”) have both recommended Sesen Bio's (the “Company”) stockholders vote “FOR” the proposal to increase the number of authorized shares of common stock by 200 mill

Sesen Bio Announces Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend “FOR” Proposal to Increase Authorized Shares

Though being an extremely volatile stock, Sesen has an intriguing pipeline of medicines. As a potential blockbuster, Vicineum already passed its Phase 3 trial with ease.

Sesen: Vicineum Could Be The Ultimate Catalyst

Adicet Bio, Inc.

Editas Medicine

Immatics NV

Sanofi

Shattuck Labs

LAVA Therapeutics has filed to raise $101 million in an IPO.

LAVA Therapeutics Seeks $101 Million U.S. IPO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Investigational New Drug (IND) application for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) submitted to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) by the Company's partner in China, Qilu Phar

Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application in China for Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full-year ended December 31, 2020. The Company's lead program, Vicineum, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In February

Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company's Lead Product Candidate Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced that on Friday, March 5, 2021 the Company submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Vicineum1 for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) under the EMA's centralized procedure. The MAA is supported by t

News for Sesen Bio Inc. Stock (SESN)